biostudies-literatureUnknown181(1)Salvarani C<h4>Importance</h4>The coronavirus disease 2019 (COVID-19) pandemic is threatening billions of people worldwide. Tocilizumab has shown promising results in retrospective studies in patients with COVID-19 pneumonia with a good safety profile.<h4>Objective</h4>To evaluate the effect of early tocilizumab administration vs standard therapy in preventing clinical worsening in patients hospitalized with COVID-19 pneumonia.<h4>Design, setting, and participants</h4>Prospective, open-label, randomized clinical trial that randomized patients hospitalized between March 31 and June 11, 2020, with COVID-19 pneumonia to receive tocilizumab or standard of care in 24 hospitals in Italy. Cases of COVID-19 were confirmed by polymerase chain reaction method with nasopharyngeal swab. Eligibility criteria inclJAMA internal medicine24-31https://www.ebi.ac.uk/biostudies/studies/S-EPMC7577199biostudies-literatureEffect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.PMC7577199Inojosa WOMilesi MRavagnani VSalvarani CPassaro ACavuto SScotton PGAngheben ABrignone ADel Bono VSainaghi PPPascale RBraglia LFacciolongo NDolci GRCT-TCZ-COVID-19 Study GroupZammarchi LBruzzi PSalio MPara OPiazza IBoni FSciascia RCostantini MDonghi LClaudio NBallerini PFFalcone MColombelli PLCodeluppi MCenderello GMassari MTurra CBertomoro PSalerno NDSecondo GMerlo DFSavoldi LTeopompi EfalseEffect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.<h4>Importance</h4>The coronavirus disease 2019 (COVID-19) pandemic is threatening billions of people worldwide. Tocilizumab has shown promising results in retrospective studies in patients with COVID-19 pneumonia with a good safety profile.<h4>Objective</h4>To evaluate the effect of early tocilizumab administration vs standard therapy in preventing clinical worsening in patients hospitalized with COVID-19 pneumonia.<h4>Design, setting, and participants</h4>Prospective, open-label, randomized clinical trial that randomized patients hospitalized between March 31 and June 11, 2020, with COVID-19 pneumonia to receive tocilizumab or standard of care in 24 hospitals in Italy. Cases of COVID-19 were confirmed by polymerase chain reaction method with nasopharyngeal swab. Eligibility criteria incl2021-01-01T00:00:00Z2021 Jan2026-04-29T10:08:23.699Z2025-02-19T03:53:34.511ZS-EPMC75771993308000510.1001/jamainternmed.2020.6615